

ITL Health Group Limited January 2019 Extraordinary General Meeting – Results of Meeting

I advise that the outcome of voting at ITL's Extraordinary General Meeting 8 January 2019 were as follows:

Resolution 1 – Removal from ASX Official Listing

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 52,463,220 (including open votes voted by the chair for)

Against: 7,532,670

Total 59,995,890

Resolution 2 – Approval of On-market buyback

The resolution was passed by a show of hands at the meeting.

The proxy votes received for the resolution were:

For: 59,712,188

Against: 299,202

Total 60,011,390

Yours faithfully

ITL Health Group Limited



Trevor Doolan
Company Secretary

ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

85,552,339

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	info@itlhealthgroup.com
Address:	Level 3, 10 Moore Street, Canberra, ACT 2601

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au

About ITL Health Group www.itlhealthgroup.com

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.